The trajectory of Sildenafil presents a complex case for stakeholders in the drug sector. While initially a tremendous success, generating billions, the patent lapse and the subsequent entry of generic competitors have considerably impacted revenue. This raises questions about the long-term profitability of similar medication projects and suggests